134,904 results match your criteria Alzheimers & Dementia[Journal]


Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.

Alzheimers Res Ther 2022 May 14;14(1):67. Epub 2022 May 14.

Clinical Memory Research Unit, Department of Clinical Sciences, Skånes universitetssjukhus, VE Minnessjukdomar, Lund University, 205 02, Malmö, Sweden.

Background: Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer's disease (AD) stages and for monitoring of treatment effects. Plasma measurements of phosphorylated tau (p-tau) are a promising biomarker for AD, but different assays show varying diagnostic and prognostic accuracies. The objective of this study was to determine the clinical performance of a novel plasma p-tau217 (p-tau217) assay, p-tau217+, and perform a head-to-head comparison to an established assay, plasma p-tau217, within two independent cohorts METHODS: The study consisted of two cohorts, cohort 1 (27 controls and 25 individuals with mild-cognitive impairment [MCI]) and cohort 2 including 147 individuals with MCI at baseline who were followed for an average of 4. Read More

View Article and Full-Text PDF

Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers.

Clin Proteomics 2022 May 14;19(1):13. Epub 2022 May 14.

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.

Background: Cerebrospinal fluid (CSF) is an important biofluid for biomarkers of neurodegenerative diseases such as Alzheimer's disease (AD). By employing tandem mass tag (TMT) proteomics, thousands of proteins can be quantified simultaneously in large cohorts, making it a powerful tool for biomarker discovery. However, TMT proteomics in CSF is associated with analytical challenges regarding sample preparation and data processing. Read More

View Article and Full-Text PDF

Do Sleep Disturbances have a Dual Effect on Alzheimer's Disease?

Cell Mol Neurobiol 2022 May 14. Epub 2022 May 14.

Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, PO Box: 1419815477, Karaj, Iran.

Sleep disturbances and Alzheimer's disease have deleterious effects on various physiological and cognitive functions including synaptic plasticity, oxidative stress, neuroinflammation, and memory. In addition, clock genes expression is significantly altered following sleep disturbances, which may be involved in the pathogenesis of Alzheimer's disease. In this review article, we aimed to discuss the role of sleep disturbances and Alzheimer's disease in the regulation of synaptic plasticity, oxidative stress, neuroinflammation, and clock genes expression. Read More

View Article and Full-Text PDF

Comment on NATSEM's report on the economic and societal cost of Alzheimer disease in Australia.

Med J Aust 2022 May 14. Epub 2022 May 14.

Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney, Sydney, NSW.

View Article and Full-Text PDF

Constructing conformational library for amyloid-β dimers as the smallest toxic oligomers using two CHARMM force fields.

J Mol Graph Model 2022 May 6;115:108207. Epub 2022 May 6.

Department of Physical Chemistry, Chemistry and Chemical Engineering Research Center of Iran, Tehran, Iran. Electronic address:

The study of amyloid-β (Aβ) dimers as the smallest toxic aggregates in the human brain suffering from Alzheimer's disease is of great interest. The structural characterization of the dimers, which is important to rationally design inhibitors for Aβ dimerization, is limited by the low stability of these species and their high tendency to aggregate into protofibrils and amyloid fibrils. Therefore, an efficient sampling method is needed for the computational study of the Aβ dimers. Read More

View Article and Full-Text PDF

Variants in the Niemann-pick type C genes are not associated with Alzheimer's disease: a large case-control study in the Chinese population.

Neurobiol Aging 2022 Apr 20;116:49-54. Epub 2022 Apr 20.

Department of Neurology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China; Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, China; Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China. Electronic address:

Despite the similar clinical and pathological features between Niemann-Pick type C (NPC) disease and Alzheimer's disease (AD), few studies have investigated the role of NPC genes in AD. To elucidate the role of NPC genes in AD, we sequenced NPC1 and NPC2 in 1192 AD patients and 2412 controls. Variants were divided into common variants and rare variants according to minor allele frequency (MAF). Read More

View Article and Full-Text PDF

Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells.

Aging Cell 2022 May 14:e13617. Epub 2022 May 14.

Departments of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA.

Alzheimer's disease (AD) is a pervasive neurodegeneration disease with high heritability. In this study, we employed CRISPR-Cas9-engineered technology to investigate the effects of a rare mutation (rs144662445) in the A kinase anchoring protein 9 (AKAP9) gene, which is associated with AD in African Americans (AA), on tau pathology and the tau interactome in SH-SY5Y P301L neuron-like cells. The mutation significantly increased the level of phosphorylated tau, specifically at the site Ser396/Ser404. Read More

View Article and Full-Text PDF

Is the Brain Undernourished in Alzheimer's Disease?

Nutrients 2022 Apr 29;14(9). Epub 2022 Apr 29.

Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.

Cerebrospinal fluid (CSF) amino acid (AA) levels and CSF/plasma AA ratios in Alzheimer Disease (AD) in relation to nutritional state are not known.

Methods: In 30 fasting patients with AD (46% males, 74.4 ± 8. Read More

View Article and Full-Text PDF

Walnut Oil Reduces Aβ Levels and Increases Neurite Length in a Cellular Model of Early Alzheimer Disease.

Nutrients 2022 Apr 19;14(9). Epub 2022 Apr 19.

Biomedical Research Center, Institute of Nutritional Sciences, Justus-Liebig-University of Giessen, Schubert-Street 81, D-35392 Giessen, Germany.

(1) Background: Mitochondria are the cells' main source of energy. Mitochondrial dysfunction represents a key hallmark of aging and is linked to the development of Alzheimer's disease (AD). Maintaining mitochondrial function might contribute to healthy aging and the prevention of AD. Read More

View Article and Full-Text PDF

Exosomes Derived from Human Amniotic Fluid Mesenchymal Stem Cells Preserve Microglia and Neuron Cells from Aβ.

Int J Mol Sci 2022 Apr 29;23(9). Epub 2022 Apr 29.

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Background: Neuroinflammation is involved in neuronal cell death that occurs in neurodegenerative diseases such as Alzheimer's disease (AD). Microglia play important roles in regulating the brain amyloid beta (Aβ) levels, so immunomodulatory properties exerted by mesenchymal stem cells may be exploited to treat this pathology. The evidence suggests that the mechanism of action of human amniotic fluid stem cells (hAFSCs) is through their secretome, which includes exosomes (exo). Read More

View Article and Full-Text PDF

Antidiabetic Drugs in the Treatment of Alzheimer's Disease.

Int J Mol Sci 2022 Apr 22;23(9). Epub 2022 Apr 22.

Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece.

The public health burden of type 2 diabetes mellitus and Alzheimer's disease is steadily increasing worldwide, especially in the population of older adults. Epidemiological and clinical studies suggest a possible shared pathophysiology between the two diseases and an increased risk of AD in patients with type 2 diabetes mellitus. Therefore, in recent years, there has been a substantial interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in Alzheimer's disease. Read More

View Article and Full-Text PDF

Agitation in Cognitive Disorders: Use of the National Alzheimer's Coordinating Center Uniform Data Set (NACC-UDS) to Evaluate International Psychogeriatric Association Definition.

Am J Geriatr Psychiatry 2022 Apr 21. Epub 2022 Apr 21.

Department of Psychiatry, Icahn School of Medicine at Mount Sinai (MS, JN, HTG, CS, AA), New York, NY; Department of Neurology, Icahn School of Medicine at Mount Sinai (AA), New York, NY.

Objective: Consensus-based definition of agitation by the International Psychogeriatric Association (IPA) has not been evaluated in community-based samples who are not preselected for behavioral disturbances. Here, we use a well-characterized cohort of community-dwelling older adults with cognitive impairment to assess the IPA criteria associated with agitation to evaluate the construction of this diagnostic entity.

Methods: We used the National Alzheimer Coordinating Center Unified Data Set (NACC-UDS) to construct the IPA consensus-based provisional definition of agitation in cognitive impairment (N = 19,424). Read More

View Article and Full-Text PDF

Assisting dementia diagnosis through the electrochemical immunosensing of glial fibrillary acidic protein.

Talanta 2022 May 5;246:123526. Epub 2022 May 5.

Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06560, Ankara, Turkey. Electronic address:

Glial fibrillary acidic protein (GFAP) is a member of the intermediate filament family of proteins with increased levels in serum and cerebrospinal fluid of patients with Alzheimer disease (AD) and other neurodegenerative diseases (NDs), such as vascular dementia (VD). This work describes the first magnetic microbeads (MBs)-based electrochemical immunoplatform for GFAP determination. The platform design comprises a sandwich immunoassay implemented on the MBs surface and amperometric transduction at single-use screen-printed carbon electrodes (SPCEs). Read More

View Article and Full-Text PDF

Quantitative imaging approaches to understanding biological processing of metal ions.

Curr Opin Chem Biol 2022 May 10;69:102152. Epub 2022 May 10.

The Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA; Department of Chemistry, Michigan State University, East Lansing, MI, USA; Department of Molecular Biosciences, Northwestern University, Evanston, IL, USA; Department of Chemistry, Northwestern University, Evanston, IL, USA; Elemental Health Institute, Michigan State University, East Lansing, MI, USA. Electronic address:

Faster, more sensitive, and higher resolution quantitative instrumentation are aiding a deeper understanding of how inorganic chemistry regulates key biological processes. Researchers can now image and quantify metals with subcellular resolution, leading to a vast array of new discoveries in organismal development, pathology, and disease. Metals have recently been implicated in several diseases such as Parkinson's, Alzheimers, ischemic stroke, and colorectal cancer that would not be possible without these advancements. Read More

View Article and Full-Text PDF

Tau modulates mRNA transcription, alternative polyadenylation (APA) profiles of hnRNPs, chromatin remodeling and spliceosome complexes.

FASEB J 2022 May;36 Suppl 1

Neurology, University of Texas Medical Branch, Galveston, TX.

Tau protein is a known contributor in several neurodegenerative diseases, including Alzheimer 's disease (AD) and frontotemporal dementia (FTD). It is well-established that tau forms pathological aggregates and fibrils in these diseases. Tau has been observed within the nuclei of neurons, but there is a gap in understanding regarding the mechanism by which tau modulates transcription and RNA processing. Read More

View Article and Full-Text PDF

Alzheimer's Disease Diagnosis With Brain Structural MRI Using Multiview-Slice Attention and 3D Convolution Neural Network.

Front Aging Neurosci 2022 26;14:871706. Epub 2022 Apr 26.

Chongqing Key Laboratory of Big Data and Intelligent Computing, Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, China.

Numerous artificial intelligence (AI) based approaches have been proposed for automatic Alzheimer's disease (AD) prediction with brain structural magnetic resonance imaging (sMRI). Previous studies extract features from the whole brain or individual slices separately, ignoring the properties of multi-view slices and feature complementarity. For this reason, we present a novel AD diagnosis model based on the multiview-slice attention and 3D convolution neural network (3D-CNN). Read More

View Article and Full-Text PDF

Cerebral Vascular Density and Its Possible Correlation with Alzheimer Disease Progression in Elderly Individuals with Rheumatoid Arthritis.

FASEB J 2022 May;36 Suppl 1

CASE, Saint Louis University School of Medicine, St. Louis, MO.

Background: Rheumatoid Arthritis (RA) is characterized by chronic systemic inflammation, primarily affecting the joints. In RA patients, high concentrations of inflammatory cytokines are found within the synovial fluid and serum (PMID: 1700672). These cytokines reduce the blood brain barrier (BBB) integrity by decreasing the expression of tight junction proteins (PMID: 29910805). Read More

View Article and Full-Text PDF

Investigating White Matter Inflammatory Cells and their Relationship with Beta-Amyloid in Alzheimer's Disease.

FASEB J 2022 May;36 Suppl 1

Anatomy & Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON.

Alzheimer's disease (AD) is a chronic neurodegenerative condition affecting millions of people worldwide. With an aging population, it is predicted that by 2050 the number of individuals living with AD will triple, resulting in an increased social and economic burden. Previous research has demonstrated that the pathological process leading to AD occurs years before a positive diagnosis. Read More

View Article and Full-Text PDF

Development of a Novel Biomarker for an early detection of Alzheimer disease.

FASEB J 2022 May;36 Suppl 1

Pharmaceutical Sciences, Texas A&M University, Kingsville, TX.

Background: Alzheimer's disease (AD), a neurodegenerative disease, is the most common form of dementia among older patients and is the 6th leading cause of death in the US. Almost 1 in 10 people over the age of 65 have AD and every 65 second someone in the US develop AD. Worldwide 30 million people have AD, and 5. Read More

View Article and Full-Text PDF

Brain dysmorphologies associated with Alzheimer disease in Down syndrome.

FASEB J 2022 May;36 Suppl 1

Alzheimer Down Unit, Department of Neurology, Alzheimer Down Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona and Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain, Barcelona.

Down syndrome (DS) is a genetic disorder occurring in 1 out of every 700 to 1,000 live births caused by trisomy of chromosome 21. The overexpression of the Amyloid Precursor Protein (APP) gene located on this chromosome leads to an early onset and rapid accumulation of ß-amyloid (Aß) in the brain that invariably results in Alzheimer Disease (AD) in people with DS. Therefore, AD, the most common form of dementia, is currently one of the most relevant medical issues in people with DS. Read More

View Article and Full-Text PDF

NCLX expression regulation by mild stress conditions.

FASEB J 2022 May;36 Suppl 1

Departamento de Bioquímica, Universidade de São Paulo, São Paulo.

Mitochondrial matrix Ca efflux is largely mediated by the mitochondrial Na /Ca exchanger (NCLX), directly coupling mitochondrial Ca and Na handling. NCLX has been shown to play a central role in many pathophysiological processes, including colorectal tumor metastasis, and Parkinson's and Alzheimer diseases. Indeed, sporadic Alzheimer´s disease patients had decreased frontal cortex NCLX levels, an effect recapitulated in mouse models. Read More

View Article and Full-Text PDF

Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer's disease.

Eur Arch Psychiatry Clin Neurosci 2022 May 13. Epub 2022 May 13.

Department of Life Sciences, Brunel University London, London, UK.

People with Alzheimer's disease (AD) and delusions have worse quality of life and prognosis. However, early markers of delusions have not been identified yet. The present study investigated whether there are any detectable differences in grey matter (GM) volume and cognitive changes in the year before symptom onset between patients with AD who did and did not develop delusions. Read More

View Article and Full-Text PDF

Alcohol and L-3-hydroxyacyl-CoA dehydrogenases activities of human Aβ-binding alcohol dehydrogenase and type 10 17β-hydroxysteroid dehydrogenase.

FASEB J 2022 May;36 Suppl 1

NYS Institute for Basic Research, Staten Island, NY.

Type 10 17β-hydroxysteroid dehydrogenase (17β-HSD10) is a mitochondrial homo-tetrameric protein necessary for brain cognitive function. It was first isolated as a human brain short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), of which the primary structure is almost identical with that of endoplasmic reticulum associated Aβ binding protein (ERAB). The finding of generalized alcohol dehydrogenase activities in ERAB prompted its renaming as the Aβ-peptide binding alcohol dehydrogenase (ABAD). Read More

View Article and Full-Text PDF

Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer's Disease.

J Mol Neurosci 2022 May 12. Epub 2022 May 12.

Neurobiology Laboratory, Centre for Biotechnology, Siksha 'O' Anusandhan (Deemed to Be University), Kalinga Nagar, Bhubaneswar-751003, India.

Since the report of "a peculiar severe disease process of the cerebral cortex" by Alois Alzheimer in 1906, it was considered to be a rare condition characterized by loss of cognition, memory impairment, and pathological markers such as senile plaques or neurofibrillary tangles (NFTs). Later on, the report was published in the textbook "Psychiatrie" and the disease was named as Alzheimer's disease (AD) and was known to be the consequences of aging; however, owing to its complex etiology, there is no cure for the progressive neurodegenerative disorder. Our current understanding of the mechanisms involved in the pathogenesis of AD is still at the mechanistic level. Read More

View Article and Full-Text PDF

Infantile Neurodegeneration results from Mutants of 17β-Hydroxysteroid Dehydrogenase Type 10 rather than Aβ-Binding Alcohol Dehydrogenase.

FASEB J 2022 May;36 Suppl 1

University of Sydney, Sydney.

Type 10 17β-hydroxysteroid dehydrogenase (17β-HSD10), a mitochondrial homo-tetrameric multifunctional protein encoded by the HSD17B10 gene is necessary for brain cognitive function. Missense mutations on this gene resulted in HSD10 mitochondrial disease, an inborn error in isoleucine metabolism. A 5-methylcytosine hotspot in this gene underlying a 388C ̵T transition leads to the HSD10(p. Read More

View Article and Full-Text PDF

Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.

Brain 2022 May 13. Epub 2022 May 13.

Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Approximately 30% of elderly adults are cognitively unimpaired at time of death despite presence of Alzheimer's disease (AD) neuropathology at autopsy. Studying individuals who are resilient to the cognitive consequences of AD neuropathology may uncover novel therapeutic targets to treat AD. It is well-established that there are sex differences in response to AD pathology, and growing evidence suggests that genetic factors may contribute to these differences. Read More

View Article and Full-Text PDF

Sensitivity to gait improvement after levodopa intake in Parkinson's disease: A comparison study among synthetic kinematic indices.

PLoS One 2022 12;17(5):e0268392. Epub 2022 May 12.

Department of Motor Sciences and Wellness, University of Naples "Parthenope", Naples, Italy.

The synthetic indices are widely used to describe balance and stability during gait. Some of these are employed to describe the gait features in Parkinson's disease (PD). However, the results are sometimes inconsistent, and the same indices are rarely used to compare the individuals affected by PD before and after levodopa intake (OFF and ON condition, respectively). Read More

View Article and Full-Text PDF

Trained immunity in viral infections, Alzheimer's disease and multiple sclerosis: A convergence in type I interferon signalling and IFNβ-1a.

Biochim Biophys Acta Mol Basis Dis 2022 May 10;1868(9):166430. Epub 2022 May 10.

Department Neurology, University of Cyprus, Lefkosia, Cyprus. Electronic address:

Type I interferon (IFN-I) signalling represents a major target for modulation in a virus' bid for latency. IFN-I perturbations are also present in such as Alzheimer's disease (AD) and multiple sclerosis (MS), where viral infections are known to increase symptomatic burden. IFN-I modulation such as via IFNβ-1a, an established MS treatment, has been researched to a limited extent to both AD and COVID-19. Read More

View Article and Full-Text PDF

β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.

Alzheimers Res Ther 2022 May 12;14(1):66. Epub 2022 May 12.

Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.

Background: Blood biomarkers that can be used for preclinical Alzheimer's disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible. Here, we investigated plasma neuronal-derived extracellular vesicle (nEV) cargo in patients along the Alzheimer's continuum, focusing on cognitively normal controls (NCs) with high brain β-amyloid (Aβ) loads (Aβ+).

Methods: The study was based on the Sino Longitudinal Study on Cognitive Decline project. Read More

View Article and Full-Text PDF

On Covid-19 and mental health: An observational study on depression, anxiety, and loneliness during the second lockdown in patients with Alzheimer disease.

Medicine (Baltimore) 2022 May 6;101(18):e29145. Epub 2022 May 6.

Unité de Gériatrie, Centre Hospitalier de Tourcoing, Tourcoing, France.

Abstract: While visiting and socialization restrictions during lockdowns were instituted to cope with the Covid-19 spread and to prolong the life of residents of retirement homes, these measures could have been expected to decrease the quality of life of their residents.We assessed longitudinal effects of the two successive lockdowns, as implemented in France, on mental health (i.e. Read More

View Article and Full-Text PDF